Drug Profile
Pegunigalsidase alfa - Chiesi/Protalix Biotherapeutics
Alternative Names: Alpha-galactosidase; CHF-6657; Elfabrio; Modified recombinant human alpha-GAL-A protein; Pegunigalsidase alfa; Pegunigalsidase alfa-iwxj; Pegunigalsidase-alfa-Protalix-Biotherapeutics; PRX-102; Recombinant human alpha galactosidase-A-Protalix; Recombinant-alpha-galactosidase-ProtalixLatest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Protalix Biotherapeutics
- Developer Protalix BioTherapeutics
- Class Enzymes; Galactosidases; Recombinant proteins
- Mechanism of Action Alpha-galactosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Fabry's disease
Most Recent Events
- 25 Mar 2024 Chiesi Farmaceutici in collaboration with ICON plc plans a phase II/III trial for Fabry's-disease (In children, In-adolescent) (IV, infusion) (NCT06328608)
- 14 Mar 2024 ProtalixBio Therapeutics plans to launch Pegunigalsidase alfa in United States, the European Union, the UK, Norway, Iceland and Liechtenstein
- 14 Mar 2024 Registered for Fabry's disease in Israel (IV) (Prior to March 2024)